These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 25104665)

  • 1. Key issues in the persistence of poliomyelitis in Nigeria: a case-control study.
    Mangal TD; Aylward RB; Mwanza M; Gasasira A; Abanida E; Pate MA; Grassly NC
    Lancet Glob Health; 2014 Feb; 2(2):e90-7. PubMed ID: 25104665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of mass immunisation campaigns and new oral poliovirus vaccines on the incidence of poliomyelitis in Pakistan and Afghanistan, 2001-11: a retrospective analysis.
    O'Reilly KM; Durry E; ul Islam O; Quddus A; Abid N; Mir TP; Tangermann RH; Aylward RB; Grassly NC
    Lancet; 2012 Aug; 380(9840):491-8. PubMed ID: 22766207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population Immunity against Serotype-2 Poliomyelitis Leading up to the Global Withdrawal of the Oral Poliovirus Vaccine: Spatio-temporal Modelling of Surveillance Data.
    Pons-Salort M; Molodecky NA; O'Reilly KM; Wadood MZ; Safdar RM; Etsano A; Vaz RG; Jafari H; Grassly NC; Blake IM
    PLoS Med; 2016 Oct; 13(10):e1002140. PubMed ID: 27701425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for the spread of vaccine-derived type 2 polioviruses after global withdrawal of trivalent oral poliovirus vaccine and the effects of outbreak responses with monovalent vaccine: a retrospective analysis of surveillance data for 51 countries in Africa.
    Cooper LV; Bandyopadhyay AS; Gumede N; Mach O; Mkanda P; Ndoutabé M; Okiror SO; Ramirez-Gonzalez A; Touray K; Wanyoike S; Grassly NC; Blake IM
    Lancet Infect Dis; 2022 Feb; 22(2):284-294. PubMed ID: 34648733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of immunization against paralytic poliomyelitis in Nigeria.
    Jenkins HE; Aylward RB; Gasasira A; Donnelly CA; Abanida EA; Koleosho-Adelekan T; Grassly NC
    N Engl J Med; 2008 Oct; 359(16):1666-74. PubMed ID: 18923171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of poliovirus vaccines against circulating vaccine-derived type 2 poliomyelitis in Nigeria between 2017 and 2022: a case-control study.
    Cooper LV; Erbeto TB; Danzomo AA; Abdullahi HW; Boateng K; Adamu US; Shuaib F; Modjirom N; Gray EJ; Bandyopadhyay AS; Zipursky S; Okiror SO; Grassly NC; Blake IM
    Lancet Infect Dis; 2024 Apr; 24(4):427-436. PubMed ID: 38246190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccine schedules and the effect on humoral and intestinal immunity against poliovirus: a systematic review and network meta-analysis.
    Macklin GR; Grassly NC; Sutter RW; Mach O; Bandyopadhyay AS; Edmunds WJ; O'Reilly KM
    Lancet Infect Dis; 2019 Oct; 19(10):1121-1128. PubMed ID: 31350192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use.
    Duintjer Tebbens RJ; Hampton LM; Thompson KM
    BMC Infect Dis; 2016 Jun; 16():237. PubMed ID: 27246198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combinations of Quality and Frequency of Immunization Activities to Stop and Prevent Poliovirus Transmission in the High-Risk Area of Northwest Nigeria.
    Duintjer Tebbens RJ; Pallansch MA; Wassilak SG; Cochi SL; Thompson KM
    PLoS One; 2015; 10(6):e0130123. PubMed ID: 26068928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study.
    O'Ryan M; Bandyopadhyay AS; Villena R; Espinoza M; Novoa J; Weldon WC; Oberste MS; Self S; Borate BR; Asturias EJ; Clemens R; Orenstein W; Jimeno J; Rüttimann R; Costa Clemens SA;
    Lancet Infect Dis; 2015 Nov; 15(11):1273-82. PubMed ID: 26318714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modeling strategies to increase population immunity and prevent poliovirus transmission in the high-risk area of northwest Nigeria.
    Kalkowska DA; Duintjer Tebbens RJ; Thompson KM
    J Infect Dis; 2014 Nov; 210 Suppl 1():S412-23. PubMed ID: 25316863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis.
    Ciapponi A; Bardach A; Rey Ares L; Glujovsky D; Cafferata ML; Cesaroni S; Bhatti A
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD011260. PubMed ID: 31801180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission.
    Thompson KM; Duintjer Tebbens RJ
    BMC Infect Dis; 2015 Sep; 15():376. PubMed ID: 26382234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of a single inactivated poliovirus vaccine dose on intestinal immunity against poliovirus in children previously given oral vaccine: an open-label, randomised controlled trial.
    John J; Giri S; Karthikeyan AS; Iturriza-Gomara M; Muliyil J; Abraham A; Grassly NC; Kang G
    Lancet; 2014 Oct; 384(9953):1505-12. PubMed ID: 25018120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preventing Vaccine-Derived Poliovirus Emergence during the Polio Endgame.
    Pons-Salort M; Burns CC; Lyons H; Blake IM; Jafari H; Oberste MS; Kew OM; Grassly NC
    PLoS Pathog; 2016 Jul; 12(7):e1005728. PubMed ID: 27384947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials.
    Sáez-Llorens X; Bandyopadhyay AS; Gast C; Leon T; DeAntonio R; Jimeno J; Caballero MI; Aguirre G; Oberste MS; Weldon WC; Konopka-Anstadt JL; Modlin J; Bachtiar NS; Fix A; Konz J; Clemens R; Costa Clemens SA; Rüttimann R
    Lancet; 2021 Jan; 397(10268):27-38. PubMed ID: 33308427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring impact of oral poliovirus vaccine on poliomyelitis trends from physiotherapy records, Ilorin, Nigeria, 1981-1988.
    Babaniyi OA; Yeya-Agba B; Parakoyi DB
    East Afr Med J; 1991 Aug; 68(8):642-8. PubMed ID: 1765018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anomalous observations on IPV and OPV vaccination.
    John TJ
    Dev Biol (Basel); 2001; 105():197-208. PubMed ID: 11763328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes.
    Thompson KM; Duintjer Tebbens RJ
    BMC Infect Dis; 2015 Sep; 15():374. PubMed ID: 26381878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progress toward poliomyelitis eradication--Nigeria, January 2013-September 2014.
    Etsano A; Gunnala R; Shuaib F; Damisa E; Mkanda P; Banda R; Korir C; Enemaku O; Corkum M; Usman S; Davis LB; Nganda Gw; Burns CC; Mahoney F; Vertefeuille JF;
    MMWR Morb Mortal Wkly Rep; 2014 Nov; 63(46):1059-63. PubMed ID: 25412063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.